13 results on '"Catherine Koering"'
Search Results
2. Supplementary Figure 1 from An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia
- Author
-
Eric Wattel, Franck Mortreux, Lydia Campos, Denis Guyotat, Jérôme Cornillon, Emmanuelle Tavernier-Tardy, Olivier Kosmider, Pierre Fenaux, Lionel Adès, Pascale Flandrin-Gresta, Patrick Auberger, Guillaume Robert, Delphine Maucort-Boulch, Aminetou Mint Mohamed, Catherine Koering, and Françoise Solly
- Abstract
Pathway enrichment analysis. For ontology analysis, gene lists were analyzed using DAVID software (KEGG pathways). The complete set of genes featured in the microarrays was used as the reference background. The three numbers on the right represent the number of deregulated mRNAs, the overall number of genes within the pathway and the p value, respectively. Data are presented for genes targeted by at least one of the 7 miRNAs and that were found repressed in SKM1 AZA resistant cells.
- Published
- 2023
- Full Text
- View/download PDF
3. Data from An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia
- Author
-
Eric Wattel, Franck Mortreux, Lydia Campos, Denis Guyotat, Jérôme Cornillon, Emmanuelle Tavernier-Tardy, Olivier Kosmider, Pierre Fenaux, Lionel Adès, Pascale Flandrin-Gresta, Patrick Auberger, Guillaume Robert, Delphine Maucort-Boulch, Aminetou Mint Mohamed, Catherine Koering, and Françoise Solly
- Abstract
Purpose: Azacitidine inhibits DNA methyltransferases, including DNMT1, and is currently the standard of care for patients with higher-risk myelodysplastic syndrome (HRMDS) or low blast count acute myeloid leukemia (AML).Experimental Design: The expression of 754 miRNAs was compared in azacitidine-resistant and azacitidine-sensitive myelodysplastic syndrome cells. We investigated the role of differentially expressed miRNAs on DNMT1 expression and azacitidine resistance in vitro. We next evaluated anti-DNMT1 miRNA expression in pretreatment bone marrow samples derived from 75 patients treated with azacitidine for HRMDS or AML.Results: Seven miRNAs, including 5 that in silico targeted the DNMT1 3′ UTR, were repressed in azacitidine-resistant cells in which DNMT1 protein levels were significantly higher. Ectopic anti-DNMT1 miRNA expression decreased DNMT1 expression and increased azacitidine sensitivity, whereas specific inhibition of endogenous anti-DNMT1 miRNAs increased DNMT1 expression and triggered azacitidine resistance. In patients treated with azacitidine, decreased expression of anti-DNMT1 miRNAs was associated with poor outcome. miR-126* had the strongest prognostic impact. Patients with miR-126*low myelodysplastic syndrome had significantly lower response rates (P = 0.04) and higher relapse rates (P = 0.03), as well as shorter progression-free (PFS; P = 0.004) and overall survival (OS; P = 0.004). Multivariate analysis showed that age, miR-126* expression, and revised International Prognostic Scoring System risk independently predicted PFS and OS. In 15 patient samples collected over time, decreased miRNA expression levels were associated with secondary resistance.Conclusions: A decreased expression of anti-DNMT1 miRNAs might account for azacitidine resistance in HRMDS and AML, and measuring miRNA expression before and during treatment might help predict primary or secondary azacitidine resistance. Clin Cancer Res; 23(12); 3025–34. ©2016 AACR.
- Published
- 2023
- Full Text
- View/download PDF
4. Differentiation is accompanied by a progressive loss in transcriptional memory
- Author
-
Camille Fourneaux, Laëtitia Racine, Catherine Koering, Sébastien Dussurgey, Elodie Vallin, Alice Moussy, Romuald Parmentier, Fanny Brunard, Daniel Stockholm, Laurent Modolo, Franck Picard, Olivier Gandrillon, Andras Paldi, and Sandrine Gonin-Giraud
- Abstract
Cell differentiation requires the integration of two opposite processes, a stabilizing cellular memory, especially at the transcriptional scale, and a burst of gene expression variability which follows the differentiation induction. Therefore, the actual capacity of a cell to undergo phenotypic change during a differentiation process relies upon a modification in this balance which favors change-inducing gene expression variability. However, there are no experimental data providing insight on how fast the transcriptomes of identical cells would diverge on the scale of the very first two cell divisions during the differentiation process.In order to quantitatively address this question, we developed different experimental methods to recover the transcriptomes of related cells, after one and two divisions, while preserving the information about their lineage at the scale of a single cell division. We analyzed the transcriptomes of related cells from two differentiation biological systems (human CD34+ cells and T2EC chicken primary erythrocytic progenitors) using two different single-cell transcriptomics technologies (sc-RT-qPCR and scRNA-seq).We identified that the gene transcription profiles of differentiating sister-cells are more similar to each-other than to those of non related cells of the same type, sharing the same environment and undergoing similar biological processes. More importantly, we observed greater discrepancies between differentiating sister-cells than between self-renewing sister-cells. Furthermore, a continuous increase in this divergence from first generation to second generation was observed when comparing differentiating cousin-cells to self renewing cousin-cells.Our results are in favor of a continuous and gradual erasure of transcriptional memory during the differentiation process.
- Published
- 2022
- Full Text
- View/download PDF
5. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML)
- Author
-
N Boissel, Lea Payen-Gay, Hussein Mortada, Pascale Flandrin-Gresta, Catherine Koering, Eric Wattel, Delphine Maucort-Boulch, Didier Auboeuf, Sandrine Hayette, Emeline Cros, Mohamed El-Hamri, Antony Ceraulo, Aminetou Mint Mohamed, Olivier Nibourel, Denis Guyotat, Isabelle Tigaud, Claude Preudhomme, Françoise Solly, Mauricette Michallet, Meyling Cheok, Lydia Campos, Franck-Emmanuel Nicolini, Franck Mortreux, Xavier Thomas, Christiane Pinatel, Charles Dumontet, and Marie Balsat
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Prognostic factor ,Acute myelogenous leukemia (AML) ,business.industry ,Complete remission ,Cytogenetics ,Hematology ,medicine.disease ,03 medical and health sciences ,Exon ,NPM1 Mutation ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Immunology ,Cohort ,Medicine ,Cumulative incidence ,business - Abstract
In AML, approximately one-third of expressed genes are abnormally spliced, including aberrant TET2 exon 2 expression. In a discovery cohort (n=99), TET2 exon 2 skipping (TET2E2S) was found positively associated with a significant reduction in the cumulative incidence of relapse (CIR). Age, cytogenetics, and TET2E2S were independent prognostic factors for disease-free survival (DFS), and favorable effects on outcomes predominated in cytogenetic normal (CN)-AML and younger patients. Using the same cutoff in a validation cohort of 86 CN-AML patients, TET2E2Shigh patients were found to be younger than TET2low patients without a difference in the rate of complete remission. However, TET2E2Shigh patients exhibited a significantly lower CIR (p
- Published
- 2017
- Full Text
- View/download PDF
6. Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML)
- Author
-
Morgan Thenoz, Claude Preudhomme, Catherine Koering, Françoise Solly, Meyling Cheok, Christiane Pinatel, Didier Auboeuf, Marie Balsat, Lydia Campos, Hussein Mortada, Charles Dumontet, Emeline Cros, Olivier Nibourel, Xavier Thomas, Lea Payen-Gay, Mohamed El-Hamri, Denis Guyotat, Aminetou Mint Mohamed, Pascale Flandrin-Gresta, Mauricette Michallet, Franck E. Nicolini, Eric Wattel, Franck Mortreux, Equipe 7, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de biologie et modélisation de la cellule ( LBMC UMR 5239 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-École normale supérieure - Lyon ( ENS Lyon ), Laboratoire d'Hématologie, Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon ( HCL ), Virologie et pathogenèse virale ( VPV ), Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon, Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de biologie et modélisation de la cellule (LBMC UMR 5239), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-École normale supérieure - Lyon (ENS Lyon)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hospices Civils de Lyon (HCL), Virologie et pathogenèse virale (VPV), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), and École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL)
- Subjects
Male ,0301 basic medicine ,Chromosomal Proteins, Non-Histone ,analysis ,Drug Resistance ,Drug resistance ,Gene mutation ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,Exon ,Bone Marrow ,Anthracyclines ,RNA, Small Interfering ,Poly-ADP-Ribose Binding Proteins ,Oncogene Proteins ,Leukemia ,Cytarabine ,Myeloid leukemia ,Exons ,Middle Aged ,3. Good health ,Leukemia, Myeloid, Acute ,Normal bone ,Oncology ,Azacitidine ,RNA Interference ,France ,Research Paper ,WT1 Proteins ,Cells ,Antineoplastic Agents ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,acute myeloid leukemia ,Cell Line ,alternative splicing ,03 medical and health sciences ,multidrug resistance ,Cell Line, Tumor ,medicine ,Humans ,Aged ,Oncogene ,business.industry ,Gene Expression Profiling ,DEK ,Oncogenes ,medicine.disease ,Molecular biology ,WT1 ,HEK293 Cells ,030104 developmental biology ,Drug Resistance, Neoplasm ,Doxorubicin ,Mutation ,business - Abstract
// Aminetou Mint Mohamed 1 , Marie Balsat 1 , Morgan Thenoz 1 , Catherine Koering 1 , Lea Payen-Gay 2 , Meyling Cheok 3 , Hussein Mortada 4 , Didier Auboeuf 4 , Christiane Pinatel 5 , Mohamed El-Hamri 6 , Charles Dumontet 7 , Emeline Cros 7 , Pascale Flandrin-Gresta 1, 8 , Olivier Nibourel 4 , Claude Preudhomme 4 , Mauricette Michallet 1, 6 , Xavier Thomas 6 , Franck Nicolini 6 , Francoise Solly 1, 8 , Denis Guyotat 1, 9 , Lydia Campos 1, 8 , Eric Wattel 1, 6, * , Franck Mortreux 1, * 1 Universite Lyon 1, CNRS UMR5239, Oncovirologie et Biotherapies, Faculte de Medecine Lyon Sud, ENS – HCL, Pierre Benite, France 2 INSERM, UMR-S1052, Centre de Recherche en Cancerologie de Lyon, Lyon, France 3 Jean-Pierre Aubert Center, INSERM U837, Facteurs de persistance des cellules leucemiques, Institute for Cancer Research in Lille, Lille cedex, France 4 Centre de Recherche sur le Cancer de Lyon, Inserm, Epissage alternatif et progression tumorale, Lyon, France 5 Centre de Recherche sur le Cancer de Lyon, Inserm, Echappement aux systemes de sauvegarde et plasticite cellulaire, Lyon, France 6 Universite Lyon I, Service d’Hematologie, Pavillon Marcel Berard, Centre Hospitalier Lyon-Sud, Pierre Benite, France 7 Centre de Recherche sur le Cancer de Lyon, Inserm, Anticorps anticancer, Lyon, France 8 Universite de Saint Etienne, Laboratoire d’Hematologie, CHU de Saint-Etienne, Saint-Etienne, France 9 Institut de Cancerologie de la Loire, CHU de Saint-Etienne, Saint Priest en Jarez, France * These authors have contributed equally to this work Correspondence to: Eric Wattel, e-mail: eric.wattel@chu-lyon.fr Franck Mortreux, e-mail: franck.mortreux@ens-lyon.fr Keywords: acute myeloid leukemia, alternative splicing, WT1, DEK, multidrug resistance Received: March 16, 2015 Accepted: April 28, 2015 Published: May 12, 2015 ABSTRACT In addition to spliceosome gene mutations, oncogene expression and drug resistance in AML might influence exon expression. We performed exon-array analysis and exon-specific PCR (ESPCR) to identify specific landscapes of exon expression that are associated with DEK and WT1 oncogene expression and the resistance of AML cells to AraC, doxorubicin or azacitidine. Data were obtained for these five conditions through exon-array analysis of 17 cell lines and 24 patient samples and were extended through qESPCR of samples from 152 additional AML cases. More than 70% of AEUs identified by exon-array were technically validated through ESPCR. In vitro , 1,130 to 5,868 exon events distinguished the 5 conditions from their respective controls while in vivo 6,560 and 9,378 events distinguished chemosensitive and chemoresistant AML, respectively, from normal bone marrow. Whatever the cause of this effect, 30 to 80% of mis-spliced mRNAs involved genes unmodified at the whole transcriptional level. These AEUs unmasked new functional pathways that are distinct from those generated by transcriptional deregulation. These results also identified new putative pathways that could help increase the understanding of the effects mediated by DEK or WT1, which may allow the targeting of these pathways to prevent resistance of AML cells to chemotherapeutic agents.
- Published
- 2015
- Full Text
- View/download PDF
7. An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia
- Author
-
Olivier Kosmider, Jérôme Cornillon, Aminetou Mint Mohamed, Eric Wattel, Patrick Auberger, Pierre Fenaux, Lydia Campos, Guillaume Robert, Emmanuelle Tavernier-Tardy, Delphine Maucort-Boulch, Lionel Ades, Pascale Flandrin-Gresta, Denis Guyotat, Françoise Solly, Catherine Koering, and Franck Mortreux
- Subjects
0301 basic medicine ,Oncology ,DNA (Cytosine-5-)-Methyltransferase 1 ,Male ,Cancer Research ,medicine.medical_specialty ,Methyltransferase ,Myeloid ,Azacitidine ,Biology ,environment and public health ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,microRNA ,medicine ,Humans ,Aged ,Aged, 80 and over ,Myeloid leukemia ,Cancer ,Middle Aged ,medicine.disease ,Prognosis ,Gene Expression Regulation, Neoplastic ,Leukemia ,Leukemia, Myeloid, Acute ,MicroRNAs ,030104 developmental biology ,medicine.anatomical_structure ,International Prognostic Scoring System ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Myelodysplastic Syndromes ,embryonic structures ,Immunology ,Female ,medicine.drug ,Signal Transduction - Abstract
Purpose: Azacitidine inhibits DNA methyltransferases, including DNMT1, and is currently the standard of care for patients with higher-risk myelodysplastic syndrome (HRMDS) or low blast count acute myeloid leukemia (AML). Experimental Design: The expression of 754 miRNAs was compared in azacitidine-resistant and azacitidine-sensitive myelodysplastic syndrome cells. We investigated the role of differentially expressed miRNAs on DNMT1 expression and azacitidine resistance in vitro. We next evaluated anti-DNMT1 miRNA expression in pretreatment bone marrow samples derived from 75 patients treated with azacitidine for HRMDS or AML. Results: Seven miRNAs, including 5 that in silico targeted the DNMT1 3′ UTR, were repressed in azacitidine-resistant cells in which DNMT1 protein levels were significantly higher. Ectopic anti-DNMT1 miRNA expression decreased DNMT1 expression and increased azacitidine sensitivity, whereas specific inhibition of endogenous anti-DNMT1 miRNAs increased DNMT1 expression and triggered azacitidine resistance. In patients treated with azacitidine, decreased expression of anti-DNMT1 miRNAs was associated with poor outcome. miR-126* had the strongest prognostic impact. Patients with miR-126*low myelodysplastic syndrome had significantly lower response rates (P = 0.04) and higher relapse rates (P = 0.03), as well as shorter progression-free (PFS; P = 0.004) and overall survival (OS; P = 0.004). Multivariate analysis showed that age, miR-126* expression, and revised International Prognostic Scoring System risk independently predicted PFS and OS. In 15 patient samples collected over time, decreased miRNA expression levels were associated with secondary resistance. Conclusions: A decreased expression of anti-DNMT1 miRNAs might account for azacitidine resistance in HRMDS and AML, and measuring miRNA expression before and during treatment might help predict primary or secondary azacitidine resistance. Clin Cancer Res; 23(12); 3025–34. ©2016 AACR.
- Published
- 2016
8. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML
- Author
-
Aminetou Mint, Mohamed, Marie, Balsat, Catherine, Koering, Delphine, Maucort-Boulch, Nicolas, Boissel, Lea, Payen-Gay, Meyling, Cheok, Hussein, Mortada, Didier, Auboeuf, Christiane, Pinatel, Mohamed, El-Hamri, Isabelle, Tigaud, Sandrine, Hayette, Charles, Dumontet, Emeline, Cros, Pascale, Flandrin-Gresta, Olivier, Nibourel, Claude, Preudhomme, Xavier, Thomas, Franck-Emmanuel, Nicolini, Françoise, Solly, Denis, Guyotat, Lydia, Campos, Mauricette, Michallet, Antony, Ceraulo, Franck, Mortreux, and Eric, Wattel
- Subjects
Male ,Age Factors ,Exons ,Middle Aged ,Prognosis ,Risk Assessment ,Disease-Free Survival ,Dioxygenases ,DNA-Binding Proteins ,Cytogenetics ,Leukemia, Myeloid, Acute ,fms-Like Tyrosine Kinase 3 ,Proto-Oncogene Proteins ,Humans ,Female ,Nucleophosmin - Abstract
In AML, approximately one-third of expressed genes are abnormally spliced, including aberrant TET2 exon 2 expression. In a discovery cohort (n=99), TET2 exon 2 skipping (TET2E2S) was found positively associated with a significant reduction in the cumulative incidence of relapse (CIR). Age, cytogenetics, and TET2E2S were independent prognostic factors for disease-free survival (DFS), and favorable effects on outcomes predominated in cytogenetic normal (CN)-AML and younger patients. Using the same cutoff in a validation cohort of 86 CN-AML patients, TET2E2S
- Published
- 2016
9. HBx triggers either cellular senescence or cell proliferation depending on cellular phenotype
- Author
-
H. Hachem, Manale El Idrissi, Catherine Koering, Eric Wattel, Morgan Thenoz, Philippe Merle, Franck Mortreux, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Virologie et pathogenèse virale (VPV), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Equipe 16, Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
0301 basic medicine ,analysis ,viruses ,Mutant ,Retinoblastoma Protein ,Hepatitis ,Viral Regulatory and Accessory Proteins ,Phosphorylation ,Promoter Regions, Genetic ,Cellular Senescence ,Liver Neoplasms ,Cell Cycle ,Hep G2 Cells ,Cell cycle ,Hepatitis B ,Phenotype ,3. Good health ,Cell biology ,Blot ,HBx ,Infectious Diseases ,Liver ,France ,Infection ,Cyclin-Dependent Kinase Inhibitor p21 ,Senescence ,Hepatitis B virus ,Cells ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Biology ,03 medical and health sciences ,Hepatitis B, Chronic ,Cell Line, Tumor ,Virology ,Humans ,Protein Precursors ,Cyclin-Dependent Kinase Inhibitor p16 ,Cell Proliferation ,Hepatitis B Surface Antigens ,Hepatology ,Cell growth ,Carcinoma ,beta-Galactosidase ,digestive system diseases ,030104 developmental biology ,Hepatocytes ,Trans-Activators - Abstract
International audience; Replicative senescence is a hallmark of chronic liver diseases including chronic hepatitis B virus (HBV) infection, whereas HBV-encoded oncoproteins HBx and preS2 have been found to overcome senescence. HBx possesses a C-terminal truncation mainly in hepatocellular carcinomas but also in noncancerous liver tissues. Here, by cell counting, BrdU incorporation, MTT proliferation assay, cell cycle analysis, SA-betagal staining and Western blotting in primary and malignant cells, we investigated the effect of HBx C-terminal mutants on cellular senescence. HBx C-terminal mutants were found to trigger cellular senescence in primary MRC5 cells, and malignant liver cells Huh7, and SK-Hep1. In contrast, these mutants promoted the proliferation of HepG2 malignant liver cells. The pro-senescent effect of HBx relied on an increased p16(INK4a) and p21(Waf1/Cip1) expression, and a decreased phosphorylation of Rb. Together, these results suggest that the two main variants of HBx present in HBV-infected liver possess opposite effects on cellular senescence that depend on the phenotype of infected cells
- Published
- 2016
- Full Text
- View/download PDF
10. Prognostic Impact of ABCA3 Expression in Pediatric Acute Myeloid Leukemia
- Author
-
Guy Leverger, Etienne Paubelle, Catherine Koering, Aminetou Mint-Mohamed, Yves Bertrand, Helene Lapillone, Antony Ceraulo, Christine Ragu, Lea Herpe, Delphine Maucort-Boulch, and Eric Wattel
- Subjects
Oncology ,medicine.medical_specialty ,education.field_of_study ,NPM1 ,Mitoxantrone ,Multivariate analysis ,business.industry ,medicine.medical_treatment ,Immunology ,Population ,Cell Biology ,Hematology ,Hematopoietic stem cell transplantation ,Bioinformatics ,Biochemistry ,Chemotherapy regimen ,Internal medicine ,Cohort ,CEBPA ,Medicine ,business ,education ,medicine.drug - Abstract
Background. Despite progress in the molecular and genetic classification of pediatric acute myeloid leukemia (AML), the prognosis remains heterogeneous. The ATP-binding cassette transporter A3 (ABCA3) seems specifically involved in the resistance of pediatric AML to intensive chemotherapy. However, studies having investigated the prognostic impact of ABCA3 expression have yielded conflicting results with respect to patient outcomes while the small sample size of these studies precluded the use of multivariate analysis. Here we investigated the prognostic impact of ABCA3 expression in a representative series of homogeneously treated pediatric AML. Methods. Samples derived from 233 patients with available high-quality RNA and enrolled in the ELAM2 protocol (NCT00149162). qRTPCR amplification of 2 conserved ABCA3 mRNA sequences was performed with GUS and ABL as reference genes. Primer sets were complementary to exons 6-7 and exons 19-20 junctions. Patients were classified according to their standardized cytogenetic and molecular (NPM1 mutations, FLT3-ITD, CEBPA double mutations) risk subgroups (Rubnitz JE, Blood 2012;119:5980-5988, Creutzig U, Blood 2012;120:3187-3205). Treatment consisted of 1 induction course (AraC and mitoxantrone) and 3 consolidation courses (course 1 and 3 with high dose AraC); all children with either intermediate or high-risk disease were candidates for hematopoietic stem cell transplant (HSCT) in complete remission (CR) after 1 to 2 consolidation courses. Results. The discovery cohort included 120 patients. Median age, median WBC, CR rate, relapse rate, median follow-up, 5-years EFS, DFS, and OS were 9.4 years, 19.3 G/L, 95%, 29%, 60 months, 58±6%, 61±6%, and 71±5 months, respectively. The two primer sets yielded consistent results (R=0.9, p Conclusion. ABCA3 expression represents an independent prognostic factor in pediatric AML. As they indicate that the level of ABCA3 expression is significantly associated with survival for currently accepted cytogenetic and molecular prognostic categories, our findings suggest that assessing ABCA3 expression will permit a better assessment of disease risk. Finally our results suggest that inhibiting ABCA3 expression, such as with indomethacin, could be beneficial in order to overcome drug resistance in pediatric AML. Disclosures No relevant conflicts of interest to declare.
- Published
- 2016
- Full Text
- View/download PDF
11. Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML)
- Author
-
Jérôme Cornillon, Catherine Koering, Olivier Kosmider, Patrick Auberger, Lydia Campos, Pascale Flandrin-Gresta, Pierre Fenaux, Aminetou Mint Mohamed, Françoise Solly, Denis Guyotat, Delphine Maucort-Boulch, Guillaume Robert, Emmanuelle Tavernier-Tardy, Eric Wattel, Franck Mortreux, and Lionel Ades
- Subjects
Oncology ,medicine.medical_specialty ,Microarray ,Performance status ,Proportional hazards model ,business.industry ,Immunology ,Azacitidine ,Myeloid leukemia ,Cell Biology ,Hematology ,Biochemistry ,medicine.anatomical_structure ,Internal medicine ,microRNA ,medicine ,Ectopic expression ,Bone marrow ,business ,medicine.drug - Abstract
Background: AZA is the standard of care for patients with either HRMDS or AML with 20-30% blasts (Oligoblastic AML). The response rate is ~50% with a median response duration of 12-15 months. The mechanisms underlying primary and secondary resistance are poorly understood and it remains difficult to accurately predict which patients will respond and in responders, to predict secondary resistance. The main factors demonstrated or suggested to interfere with response to AZA and/or survival include marrow blast percentage, performance status, IPSS cytogenetic risk, presence of peripheral blasts, transfusion dependency, IPSS-R risk, mutations of TET2, P53, IDH1/2, and DNMT3A, elevated expression of BCL2L10, Fas, or PI-PLCbeta1. Deregulation of microRNAs is a hallmark of MDS, yet its consequences on AZA efficacy have not been specifically addressed in HRMDS. Methods: We measured the expression of 754 miRNAs in SKM1 MDS cells resistant or sensitive to AZA. miRNAs of interest were ectopically expressed or specifically inhibited in HEK293T cells which were assayed for AZA sensitivity (MTT). Seven miRNAs were quantified in bone marrow mononuclear cells deriving from 75 patients with HRMDS (n= 50) or oligoblastic AML treated with AZA [median age 74, 24 females, median cycle number 6, (1-39)]. Results: Seven miRNAs (miR-125a-5p, miR-99b-5p, miR-126, miR-126*, hsa-let-7c, miR-34b-3p, and miR-10b*) that include 6 tumor-suppressor miRNAs, were found differentially expressed between AZA-sensitive versus -resistant cells; all being transcriptionally repressed in resistant cells. In silico, 5 of these miRNAs were found to target the 3' UTR of DNA methyltransferase 1 (DNMT1) while Zhao et al. [Arthritis & rheumatism, 2011; 63(5)] have shown that miR-126 directly inhibits DNMT1 translation. DNMT1 is one of the main AZA molecular target, the higher the level of DNMT1 expression, the lower the AZA sensitivity [Li et al., Cancer biology & therapy, 2010; 9(4)]. Microarray and western blotting showed that levels of DNMT1 protein, but not mRNA, were significantly higher in AZA-resistant cells. In HEK293T cells, specific endogenous miR-126/126* inhibition significantly augmented DNMT1 protein expression and triggered AZA-resistance, as measured through MTT proliferation assay. In the same cells, ectopic expression of miR-126/126* decreased DNMT1 protein expression in a concentration-dependent manner. In the 75 patients treated with AZA, a decreased expression level of all but miR-10* was associated with decreased response rate (IWG 2006 criteria) and poor outcome; miR-126/126* having the strongest prognostic impact. When compared with miR-126*High MDS, miR-126*Low MDS had significantly lower overall response rate (37% versus 60%, p=0.04), higher relapse rate (100% versus 71%, p=0.034), shorter progression-free (PFS) (8±8% versus 49±12% at 3 years, p=0.004, log rank test), and overall survival (OS) (16±6% versus 46±9%, p=0.004). Baseline patient characteristics of the 2 groups were similar. Multivariate analyses were performed using the Cox proportional hazards model. Table 1 shows that age, miR-126* expression, and IPSS-R risk independently predicted PFS and OS. miRNAs expression was analyzed over time in 15 patients. The mean expression level of 5/7 miRNAs increased over time in the 10 responders without statistically significant difference (DNS) between the first and latest values. In contrast, the expression of 7/7 miRNAs decreased over time in the 5 patients with treatment failure, the difference being statistically significant for 2 miRNAs (p²0.043, Wilcoxon test). Secondary resistance occurred in 7/10 responders and was found associated with a decreased expression of 6/7 miRNAs (p²0.044 for 4 miRNAs) versus 2/7 (DNS) in the 3 long-term responders. Conclusion: Our results suggest that in HRMDS and oligoblastic AML, i. primary or secondary resistance to AZA is associated with the decreased expression of anti-DNMT1 tumor-suppressor microRNAs that trigger AZA resistance in vitro; ii. measuring miRNAs expression before and under treatment might help to predict primary or secondary AZA resistance and thereby to rapidly offer alternative treatment; iii. increasing AZA exposure might help to circumvent AZA resistance in case of either low or decreased anti-DNMT1 miRNA concentration while using anti-DNMT1 microRNAs as a therapeutic tool might increase or restore AZA sensitivity. Disclosures Fenaux: Janssen: Honoraria, Research Funding; Celgene Corporation: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Wattel:AMGEN: Consultancy, Research Funding; PIERRE FABRE MEDICAMENTS: Research Funding; CELGENE: Research Funding, Speakers Bureau; NOVARTIS: Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding.
- Published
- 2015
- Full Text
- View/download PDF
12. TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy
- Author
-
Lydia Campos, Françoise Solly, Xavier Thomas, Emeline Cros, Meyling Cheok, Franck Mortreux, Olivier Nibourel, Didier Auboeuf, Lea Payen-Gay, Mohamed Elhamri, Hussein Mortada, Pascale Flandrin-Gresta, Catherine Koering, Denis Guyotat, Delphine Maucort-Boulch, Isabelle Tigaud, Eric Wattel, Charles Dumontet, Marie Balsat, Aminetou Mint Mohamed, Claude Preudhomme, and Franck E. Nicolini
- Subjects
Oncology ,Univariate analysis ,NPM1 ,education.field_of_study ,medicine.medical_specialty ,Immunology ,Azacitidine ,Population ,Decitabine ,Cell Biology ,Hematology ,Gene mutation ,Biology ,Biochemistry ,Molecular biology ,Exon ,Internal medicine ,medicine ,Cytarabine ,education ,medicine.drug - Abstract
The nucleoside analogue cytarabine (AraC) has served as the backbone of acute myeloid leukemia (AML) treatment for nearly forty years. About one-third of expressed genes are abnormally spliced in AML yet alternative exon usage (AEU) plays a role in the plasticity of tumor cells and may influence the response to treatment. Here the exon expression profiles of the erythroleukemia K562 cell line were compared to that of its AraC-resistant variant K562/AraC through Affymetrix HTA2 exon arrays. 5140 exon events harbored by 2583 genes distinguished the 2 cell lines. Among these, the skipping of TET2 exon 2 was identified in K562 cells sensitive to AraC whereas TET2 gene expression remained unchanged at the whole transcript level. The results were confirmed by exon-specific RTPCR (ESPCR). Microarray analysis did not evidenced any significant change in mRNA splicing for the 10 remaining exons of the TET2 gene. TET2 is a dioxygenase that catalyzes the conversion of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) and promote DNA demethylation. TET2 somatic mutations occur in about 25% AML, distributing across the whole coding sequence without obvious hot spots. These mutations decrease TET2 enzymatic activity by truncating the protein or affecting its catalytic activity. TET2 exon 2 is spliced in a mutually exclusive manner with exon 1 yet it is used as an alternative promoter (https://fasterdb.lyon.unicancer.fr/). However, TET2 exon 2 is not translated into protein and its role in TET2 regulation is still unknown. Having found that AraC sensitive cells harbor the spliced TET2 isoform, we investigated whether or not skipping of TET2 exon 2 correlate with disease outcome in AML patients treated with AraC-based intensive chemotherapy (AraC-IC). The discovery cohort included 106 consecutive AML patients treated with AraC-IC (median age 57.91, 64 males). RNA was extracted from bone marrow MNCs and assayed for TET2 exon 2 skipping through real-time quantitative ESRTPCR (qESRTPCR) amplification of E1E3 (spliced) and E2E3 (unspliced) TET2 isoforms. TET2 exon 2 skipping was quantified by calculating the ratio E1E3/E2E3. For statistical analysis, the ratio E1E3/E2E3 was dichotomized using median value as the cutoff value. Skipping of TET2 exon 2 was associated with a significantly lower response rate: 65% vs 92%, p = 0.001 but with a significantly lower relapse rate: 39% vs 85%: p In conclusion TET2 exon 2 skipping is associated with a low relapse rate and possesses a strong favorable prognostic impact in AML treated with AraC-CTI. The mechanism linking this alternative exon usage with resistances to AraC are currently investigated while our results suggest that the determination of TET2 exon 2 splicing status might assist risk stratification. Disclosures Nicolini: Novartis: Consultancy.
- Published
- 2014
- Full Text
- View/download PDF
13. Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics
- Author
-
Xavier Thomas, Lydia Campos, Françoise Solly, Hussein Mortada, Meyling Cheok, Didier Auboeuf, Morgan Thenoz, Lea Payen-Gay, Franck E. Nicolini, Mohamed Elhamri, Isabelle Tigaud, Aminetou Mint Mohamed, Charles Dumontet, Franck Mortreux, Emeline Cros, Delphine Maucort-Boulch, Eric Wattel, Catherine Koering, Olivier Nibourel, Claude Preudhomme, Denis Guyotat, and Pascale Flandrin-Gresta
- Subjects
NPM1 ,Immunology ,Alternative splicing ,ATP-binding cassette transporter ,Cell Biology ,Hematology ,Biology ,ABCA3 ,Gene mutation ,Biochemistry ,Molecular biology ,Exon skipping ,Exon ,RNA splicing ,biology.protein - Abstract
ATP binding cassette (ABC) transporters are a superfamily of highly conserved membrane proteins that transport a wide variety of substrates across cell membranes and confer drug resistance against a wide range of chemotherapeutic agents. We recently found that WT1, which is regularly overexpressed in AML and interact with the splicing machinery, modifies the splicing of ABC transporters A2, A3, A5, and C2. For ABCA3, WT1 knock-down in three AML cell line coupled with Affymetrix HTA2 exon arrays analysis confirmed by exon-specific PCR revealed that WT1 influences the skipping of exon 19. ABCA3 belongs in the ABC subclass and induces a significant reduction in cytotoxicity observed following exposure to DNR, mitoxantrone, etoposide, Ara-C and vincristine. The ABCA3 domain encoded by exon 19 (amino acid 805-847) is localized at the junction of the first nucleotide-binding domain and the second transmembrane domain, and is involved in ATP hydrolysis. In silico, skipping of exon 19 deletes a sequence of 32 amino acids rich in positively charged residues and is thereby assumed to increase drug efflux through increased ATP hydrolysis. The effects of the skipping of exon 19 on chemoresistance and DNR efflux are currently investigated while for the present study, we hypothesized that skipping of exon 19 of ABCA3 might negatively influence outcome in AML patients. Analyzing 132 bone marrow AML samples harvested at diagnostic confirmed the statistically significant correlation between WT1 expression and ABCA3 splicing in vivo (p In order to confirm these results we investigated the prognostic impact of ABC A3 exon 19 skipping in a validation cohort of 108 additional AML case with normal cytogenetics. FLT3 internal tandem duplication (FLT3-ITD) and nucleophosmin (NPM1) exon-12 gene mutation were identified in 37 (34.3%) and 66 cases (61.1%). In the 86 patients treated with IC, the CR rate was 89,5% without significant difference between patients with or without exon 19 skipping. The relapse rate was higher in cases with exon 19 skipping (47,1% vs 23.5%) but the difference was not statistically significant. The 29 allografted patients were censored at the time of allograft. Median follow-up was 12 months. By univariate analysis ABC-A3 exon skipping of exon 19 significantly affected DFS (HR=2.03 (95% confidence interval: 1.22-3.39), p=0.007, and EFS (HR 1.62 (95% confidence interval: 1.06-2.48), p=0.027); higher the level of exon 19 skipping, poorer the outcome. In multivariate analysis, age, FLT3-ITD, ABC A3 exon 19 skipping but not NPM1 mutation were identified to be independent prognostic factors for EFS while FLT3-ITD and ABC A3 exon 19 skipping were independent prognostic factors for DFS. In conclusion ABC-A3 missplicing possesses a strong prognostic impact in AML indicating that besides whole gene transcription, quantitative analysis of alternative splicing might represent a promising tool for assessing AML aggressiveness at the time of diagnostic in patients with normal or abnormal karyotype. Disclosures Nicolini: Novartis: Consultancy.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.